Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow
…
4,290$
-0,92%
Echtzeit-Aktienkurs Abeona Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Abeona Therapeutics Inc. Aktie
Abeona Therapeutics: Maintaining Buy On ZEVASKYN Launch Potential For RDEB
…
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do…
ABEO: Momentum Building for Zevaskyn®
By David Bautz, PhDNASDAQ: ABEOREAD THE FULL ABEO RESEARCH REPORTBusiness UpdateMomentum Building for Zevaskyn®Abeona Therapeutics, Inc. (NASDAQ: ABEO) has successfully…
Abeona (ABEO) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATETuesday, March 17, 2026 at 8:30 a.m. ETCALL PARTICIPANTSChief Executive Officer — Vishwas SeshadriChief Commercial Officer…
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead
…
Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?
Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.…
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
…
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript
…
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
…
Areteia Therapeutics gibt die Ernennung von Donald J. Hayden, Jr. und Ian F. Smith in den Vorstand bekannt
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“) gab heute bekannt, dass der Vorstand mit sofortiger Wirkung Donald J. Hayden,…
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?
Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far…
Areteia Therapeutics präsentiert auf der 43. jährlichen J.P. Morgan Healthcare Conference am Dienstag, den 14. Januar 2025
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“), ein Biotechnologieunternehmen im klinischen Stadium, das neuartige Entzündungs- und Immuntherapien entwickelt, mit…
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical…
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity…
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced…
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity…
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Beam Therapeutics Announces Transition of Chief Financial Officer
CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision…
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeonas Patented AAV204 Capsid for Select Ophthalmology Indications
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene…
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic…
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity…
Abeona Therapeutics initiated with Buy at Stifel
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Abeona Therapeutics CEO purchases $32,000 in company stock By Investing.com
Abeona Therapeutics CEO purchases $32,000 in company stock…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a…
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported…
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity…
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical…
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…